DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1942)

Gastroesophageal Cancer | Landscape & Forecast | Disease Landscape & Forecast

Gastroesophageal Cancer | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Market Outlook

Therapeutic options for gastroesophageal cancer are limited; only two targeted agents are approved to treat gastric and GEJ adenocarcinoma in the major pharmaceutical markets under study, and neither agent is approved to treat esophageal cancer. Roche/Genentech/Chugai’s Herceptin is the first-line standard of care for HER2-positive metastatic patients, and Eli Lilly’s Cyramza is approved for patients with advanced disease following fluoropyrimidine- and platinum-based therapy. Additionally, two PD-1 inhibitors—Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo (Japan only) and Merck & Co.’s Keytruda (United States only)—are approved to treat third- and later-line gastric and GEJ adenocarcinoma. Despite these approvals, the gastroesophageal cancer therapy market is largely untapped and thus represents a lucrative opportunity for drug developers. The late-phase pipeline is buoyant; agents span a range of drug classes and target various gastroesophageal cancer populations associated with significant unmet need. These treatments may soon offer patients a more-optimistic outlook.

Questions Answered

  • How do current treatment practices differ between esophageal, gastric, and GEJ cancer, and which populations provide the greatest drug-treatment opportunities by geography?
  • What are interviewed thought leaders’ insights on Herceptin, Cyramza, Keytruda, Opdivo, and chemotherapy? What clinical needs remain unfulfilled, and on which opportunities can developers capitalize?
  • Which other immune checkpoint inhibitors (Bavencio, Yervoy, tislelizumab) are expected to be approved and in which disease setting(s), and how will they compete with currently marketed and established therapies?
  • What agents with novel mechanisms of action are being assessed in Phase III trials, which populations are they targeting, and how will they impact the gastroesophageal cancer therapy market?
  • What are the market drivers and constraints in the gastroesophageal market, and how will the market evolve over the forecast period?

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • March 2019
      • December 2018
      • October 2018
      • July 2018
      • May 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Gastroesophageal Cancer?
        • What Factors Are Constraining the Market for Gastroesophageal Cancer?
      • Segment-Specific Trends
        • Localized and Resectable Locally Advanced Gastroesophageal Cancer
        • Unresectable Locally Advanced Gastroesophageal Cancer
        • First-Line HER2-Negative Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
        • First-Line HER2-Positive Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
        • First-Line Metastatic Esophageal Cancer
        • Second-Line HER2-Negative Gastric and Gastroesophageal Junction Adenocarcinoma
        • Second-Line HER2-Positive Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
        • Second- and Third-Line Metastatic Esophageal Cancer
        • Third- and Fourth-Line HER2-Positive Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Disease Pathophysiology
        • Anatomy of the Stomach and the Gastroesophageal Junction
        • Anatomy of the Esophagus
        • Histological Subtypes and Development of Gastric and Gastroesophageal Junction Adenocarcinoma
        • Histological Subtypes and Development of Esophageal Cancer
      • Staging and Classification
      • Key Pathways and Drug Targets
    • Epidemiology
      • Introduction
        • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution
        • Recurrent Incident Cases
        • Molecular Subtypes
        • Drug-Treatable Populations of Gastroesophageal Cancer
        • Drug-Treated Populations of Gastroesophageal Cancer
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Angiogenesis Inhibitors
        • HER2 Inhibitors
        • Immune Checkpoint Inhibitors
      • Medical Practice
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Gastroesophageal Cancer
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Gastroesophageal Cancer
        • Immune Checkpoint Inhibitors
        • HER2 Inhibitors
        • Angiogenesis Inhibitors
        • Therapeutic Vaccines
        • PARP Inhibitors
        • Cytotoxic Agents
        • Matrix Metalloproteinase Inhibitors
        • Claudin Inhibitors
        • FGFR Inhibitors
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Gastroesophageal Cancer
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecasting Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Gastroesophageal Cancer Bibliography

Already a Client? Log in to access this report.

  • Pub Date: March 2019
  • Author(s): Ann-Marie Looney, M.Sc., Ph.D; Paul Wilcock. PhD; Johnson Olabisi, MBBS, MSc
  • Ann-Marie Looney, is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr Looney worked as a postdoctoral researcher for the National Children’s Research Centre and the Irish Centre for Fetal and Neonatal Translational Research, Ireland where her work centred on the discovery and validation of biomarkers of early childhood injury and disease, with a specific focus on early childhood obesity, neonatal brain injury and autism spectrum ; She has a in Neuroscience, a by research in molecular biology and a in clinical and translational research from University College Cork, Ireland.

  • Since October 2015, Dr. Wilcock has been a Business Insights Analyst in the oncology team at Decision Resources Group. He has experience in various indications including metastatic malignant melanoma and renal cell carcinoma, and will have a major focus on gastric cancer going forward. Previously, Dr. Wilcock was a Research Funding Manager at Cancer Research UK, where he developed a deep understanding of drug discovery, predominantly in the academic setting. He gained his doctorate from the University of Manchester where he utilized Systems Biology to explore the role of cell signaling and hypoxia in oral cancer.

  • Johnson joined Decision Resources Group (DRG) in 2015 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with his particular interests in the oncology space. Prior to joining DRG, he trained as a community physician where he was involved in primary (patient) care, primary health care and various community research & activities. He has also supervised and coordinated various governmental and non-governmental public health projects. Johnson holds a Masters of Science in Public Health (Health Economics) degree from the London School of Hygiene and Tropical Medicine with a Masters in Epidemiology and Medical Statistics & a Medical degree from the University of Ibadan, Nigeria.  

Purchase Report

Recent reports:
You may also be interested in: